Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statementSarah P. Blagden, A. Yiangou, Alison M. Cooper et al.|British Journal of Cancer|2020Cited by 44
Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies: Safety and proof of mechanism.Martijn P. Lolkema, Sarah P. Blagden, Elizabeth Ruth Plummer et al.|Journal of Clinical Oncology|2019Cited by 1